X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to evaluate the molecular MOA of EvolveImmune’s proprietary costimulatory T cell engager platform, EVOLVE, designed to unleash potent, selective, and integrated T cell costimulation to address unmet needs for the treatment of solid and hematologic tumor.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Cell and Gene therapy
Recipient: EvolveImmune Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 14, 2023
Details:
Under the collaboration, University of Oxford and Selvita will advance potential therapeutics in the area of Parkinson's disease and have developed promising prototype compounds that efficiently promote the clearance of alpha-synuclein aggregates.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Recipient: Selvita S.A
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 05, 2023
Details:
Nigeria has granted provisional approval to Oxford University's R21 malaria vaccine which is composed of R21 Malaria antigen 5µg and Matrix-M1 50µg as an adjuvant.
Lead Product(s): R21 Malaria Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: R21
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2023
Details:
The focus of the agreements is to apply the innovative technologies and research capabilities of the respective academic groups to identify, validate and prioritize key GPCRs driving gastrointestinal and immune disorders, including IBD, as targets for SBDD.
Lead Product(s): Undisclosed
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Recipient: Sosei Heptares
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 08, 2022
Details:
ChAdOx1 biEBOV provided as a liquid in glass vials and administered intramuscularly into the deltoid of the non-dominant arm. The vaccine will be administered intramuscularly (IM).
Lead Product(s): ChAdOx1 biEBOV
Therapeutic Area: Infections and Infectious Diseases Product Name: ChAdOx1 biEBOV
Highest Development Status: Phase IProduct Type: Vaccine
Recipient: Serum Institute of India
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 17, 2022
Details:
The signing of amendment, as well as additional funding provided by BWV, will enable Oxford to continue research and optimization of the Company’s universal influenza vaccine candidate, BWV-101.
Lead Product(s): BWV-101
Therapeutic Area: Infections and Infectious Diseases Product Name: BWV-101
Highest Development Status: PreclinicalProduct Type: Vaccine
Recipient: Blue Water Vaccines
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 31, 2022
Details:
The study achieved primary endpoint of reduction in nodule hardness at 12 months and secondary endpoint of reduction in nodule size at multiple time points including 12 months for anti-TNF injections adalimumab.
Lead Product(s): Adalimumab
Therapeutic Area: Dermatology Product Name: Humira
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: 180 Life Sciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 29, 2022
Details:
Developing Elysium Health's proprietary algorithmic platform for epigenetic examination (APEX), and the company's biological age measure Index, Elysium Health plans to utilize the VITACOG biobank to explore the development and commercialization of novel brain health measures.
Lead Product(s): Micronutrient-based Dietary Supplement
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Recipient: Elysium Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 23, 2022
Details:
Together with the University of Oxford, the Company plans to proceed with scaling up and Good Manufacturing Practice (GMP) production of HMGB1, as well as safety and toxicity testing in preparation for a planned Investigational New Drug (IND) application filing.
Lead Product(s): HMGB1
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: HMGB1
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: 180 Life Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 15, 2021
Details:
Com-COV3 study includes Novavax' recombinant nanoparticle COVID-19 vaccine candidate, NVX-CoV2373, is one of the three COVID-19 vaccines that combined regimens that mix vaccines from different manufacturers to achieve immune protection against COVID-19.
Lead Product(s): NVX-CoV2373,Matrix-M1
Therapeutic Area: Infections and Infectious Diseases Product Name: Covovax
Highest Development Status: Phase IIIProduct Type: Vaccine
Recipient: Novavax
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 16, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
